As LAG-3 blocking mAbs are currently tested in 28 different clinical trials for the treatment of cancer, we evaluated Nbs specific for the inhibitory immune checkpoint LAG-3 and used these for noninvasive imaging of moLAG-3. The gene discussed is LAG3; the disease is cancer.